How have PMD shares performed in 2024?

Psychemedics' stock was trading at $2.96 at the beginning of 2024. Since then, PMD stock has decreased by 13.5% and is now trading at $2.56. View the best growth stocks for 2024 here .

When is Psychemedics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PMD earnings forecast .

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) issued its earnings results on Thursday, March, 28th. The company reported ($0.16) EPS for the quarter. The company earned $5 million during the quarter. Psychemedics had a negative net margin of 18.39% and a negative trailing twelve-month return on equity of 48.68%.

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be given a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 10.94%. The ex-dividend date of this dividend is Wednesday, May 24th. Read our dividend analysis for PMD .

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com . Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE) , Dominion Energy (D) , Sorrento Therapeutics (SRNE) , AT&T (T) , AbbVie (ABBV) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , Pattern Energy Group (PEGI) and Simon Property Group (SPG) .

How do I buy shares of Psychemedics?

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PMD

Psychemedics (PMD) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free PMD Stock Alerts

$2.56

+0.02 (+0.79%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.56
▼
$2.56
50-Day Range: $2.54
▼
$3.18
52-Week Range: $2.06
▼
$5.59

Volume: 740 shs
Average Volume: 11,782 shs
Market Capitalization: $14.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Psychemedics alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Psychemedics Stock (NASDAQ:PMD)

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.

PMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PMD Stock News Headlines

March 28, 2024 | investorplace.com

PMD Stock Earnings: Psychemedics Reported Results for Q4 2023

March 28, 2024 | globenewswire.com

Psychemedics Corporation Reports 2023 Financial Results

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | globenewswire.com

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

January 3, 2024 | bizjournals.com

Small cap drug testing company relocates HQ to DFW from Massachusetts

January 2, 2024 | msn.com

Massachusetts drug testing firm targeting fentanyl relocates corporate HQ to Dallas

January 2, 2024 | markets.businessinsider.com

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

November 10, 2023 | msn.com

Psychemedics reports Q3 results

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 9, 2023 | finance.yahoo.com

Psychemedics Corporation Reports Third Quarter 2023 Financial Results

November 9, 2023 | morningstar.com

Psychemedics Corp PMD

October 27, 2023 | finance.yahoo.com

Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

September 26, 2023 | benzinga.com

Psychemedics Chief Revenue Officer Awarded $448K Worth of Stock Options

September 22, 2023 | benzinga.com

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

September 21, 2023 | msn.com

Do You Get PMS? You Could Be Headed for Early Menopause, Study Shows

August 22, 2023 | benzinga.com

President & CEO at Psychemedics Acquires Company Stock Options Worth 300,000 Shares

August 18, 2023 | finance.yahoo.com

Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2023 | marketwatch.com

Psychemedics 2Q Loss Widens Amid Labor Shortage, Settlement

August 11, 2023 | marketwatch.com

Psychemedics Eliminates Dividend

August 11, 2023 | finance.yahoo.com

Psychemedics Corporation Reports Second Quarter 2023 Financial Results

July 12, 2023 | marketwatch.com

Psychemedics Taps Brian Hullinger as Successor of Long-Time CEO Ray Kubacki

July 12, 2023 | finance.yahoo.com

Psychemedics Corporation Announces CEO Succession Plan

May 19, 2023 | msn.com

Psychemedics's Ex-Dividend Date Is Wednesday, Here's What You Need To Know

May 19, 2023 | finance.yahoo.com

Do These 3 Checks Before Buying Psychemedics Corporation (NASDAQ:PMD) For Its Upcoming Dividend

May 13, 2023 | finance.yahoo.com

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

May 12, 2023 | msn.com

Psychemedics (PMD) Declares $0.07 Dividend

May 10, 2023 | msn.com

Psychemedics declares $0.07 dividend

See More Headlines

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:PMD
CUSIP: N/A
CIK: 806517
Web: www.psychemedics.com
Phone: (978) 206-8220
Fax: 978-264-9236
Employees: 133
Year Founded: 1985

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,150,000.00
Net Margins: -18.39%
Pretax Margin: -15.56%
Return on Equity: -48.68%
Return on Assets: -26.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.45
Quick Ratio: 1.45

Sales & Book Value

Annual Sales: $22.10 million
Price / Sales: 0.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.15 per share
Price / Book: 2.23

Miscellaneous

Outstanding Shares: 5,810,000
Free Float: 4,413,000
Market Cap: $14.87 million
Optionable: Not Optionable
Beta: 0.64

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian Hullinger
President, CEO & Director
Dr. Werner A. Baumgartner Ph.D.
Founder
Ms. Annette Baumgartner
Founder
Daniella Mehalik
Vice President of Finance
Mr. Michael Weisenhoff (Age 34)
Principal Financial & Accounting Manager
Ms. Shannon Shoemaker
Chief Revenue Officer
Mr. Patrick J. Kinney Jr.
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PMD Stock Analysis - Frequently Asked Questions

How have PMD shares performed in 2024?: Psychemedics' stock was trading at $2.96 at the beginning of 2024. Since then, PMD stock has decreased by 13.5% and is now trading at $2.56.
View the best growth stocks for 2024 here.
When is Psychemedics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PMD earnings forecast.
How were Psychemedics' earnings last quarter?: Psychemedics Co. (NASDAQ:PMD) issued its earnings results on Thursday, March, 28th. The company reported ($0.16) EPS for the quarter. The company earned $5 million during the quarter. Psychemedics had a negative net margin of 18.39% and a negative trailing twelve-month return on equity of 48.68%.
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?: Psychemedics declared a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be given a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 10.94%. The ex-dividend date of this dividend is Wednesday, May 24th.
Read our dividend analysis for PMD.

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?: 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.
What other stocks do shareholders of Psychemedics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).
How do I buy shares of Psychemedics?: Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Psychemedics (PMD) Stock Price, News & Analysis

About Psychemedics Stock (NASDAQ:PMD)

PMD Stock Price History

PMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PMD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info